Skip to main content

Table 1 Summary of telaprevir antiviral activity in patients infected with G4 HCV

From: Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

Antiviral activity

Patients infected with G4 HCV

 

T (N = 8)

TPR (N = 8)

PR (N = 8)

 

n (%)

n (%)

n (%)

Virologic responsea

   

By end of TVR/Pbo treatment

0

1 (12.5%)

0

By EOT

7 (87.5)

6 (75.0)

6 (75.0)

Cumulative viral breakthrough

   

By end of TVR/Pbo treatment

5 (62.5)

0

0

By EOT

5 (62.5)

2 (25.0)

1 (12.5)

Missing follow-up datac

1

0

0

Relapseb

1/7 (14.3)

2/6 (33.3)

1/6 (16.7)

SVR24

5 (62.5)

4 (50.0)

5 (62.5)

  1. aHCV RNA <25 IU/mL undetectable; bn/N (%) where N = Number of patients with undetectable HCV RNA at EOT; cPatients with undetectable HCV RNA at EOT for which no HCV RNA measurements were available at follow-up Week 24.
  2. EOT: End of treatment; G: genotype; HCV: Hepatitis C virus; n: number of patients with observation; PR: Peginterferon/ribavirin arm; T: Telaprevir monotherapy arm; T/PR: Telaprevir plus peginterferon/ribavirin arm; SVR24: Sustained virologic response at 24 weeks after last study dose.